FDA grants IDE to Orchestra BioMed for cardiac neuromod trial

Orchestra BioMed (Nasdaq:OBIO) announced today that the FDA granted investigational device exemption (IDE) for its BACKBEAT trial.

Related Keywords

,David Hochman ,David Kandzari ,Piedmont Heart Institute In Atlanta ,Medtronic ,Orchestra Biomed ,Pennsylvania Based Orchestra Biomed ,Piedmont Heart Institute ,